The utility of BNP and NT-proBNP in guiding management of HF is still unclear, with some evidence suggesting biomarker-guided therapy reduces mortality [137] and some evidence finding no difference compared with symptom-guided management [138,139]. This evidence concerns the gene NPPB and hydrops fetalis.